Goldman Sachs Reiterates Buy Rating on Iovanace Biotherapeutics (IOVA)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
H.C. Wainwright Reiterates Buy Rating on Iovanace Biotherapeutics (IOVA)
June 3, 2025 7:05 AM EDTH.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating and $20.00 price target on Iovanace Biotherapeutics (NASDAQ: IOVA).
The analyst commented: "In addition to disclosing updated data from C-144-01 and hosting a KOL discussion, Iovance presented poster a detailing its ongoing clinical trial assessing TIL therapy in solid tumors, including NSCLC. Recall, IOV-COM-202 is an open-label Phase 2 study evaluating lifileucel in solid tumors; cohort 3A is... More
Citizens JMP Reiterates Market Perform Rating on Iovanace Biotherapeutics (IOVA)
June 3, 2025 4:23 AM EDTCitizens JMP analyst Reni J. Benjamin reiterated a Market Perform rating on Iovanace Biotherapeutics (NASDAQ: IOVA).
The analyst commented, We reiterate our Market Perform rating on Iovance Biotherapeutics based on a discounted revenue multiple analysis. During ASCO, Iovance presented five-year outcomes from the C-144-01... More
Iovance Biotherapeutics (IOVA) Announces Publication on Amtagvi
June 2, 2025 9:30 AM EDTIovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that the Journal of Clinical Oncology has published the final analysis from the Phase 2 C-144-01 clinical trial evaluating the individualized T cell therapy Amtagvi® (lifileucel) in patients with advanced melanoma. These five-year follow-up results are being simultaneously presented during an oral session today at the 2025 American Society of... More
Citizens JMP: Standard of Care Modifying Regimens at ASCO 2025
May 30, 2025 5:01 AM EDTCitizens JMP released an industry report discussing the abstract titles from companies in the firms coverage, and outside, to be presented at the 2025 American Society of Clinical Oncology (ASCO) annual meeting.
The analyst commented, Abstract titles for presenting companies were released on April 23. Companies in the Citizens' coverage... More
